Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AES Corp (AES) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

AES Corp vs Recursion Pharmaceuticals Inc — how do they compare? AES Corp trades at $14.66 (market cap $10.51B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: AES Corp is far larger — about 5.9× Recursion Pharmaceuticals Inc's market cap, and AES Corp pays a 4.78% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

AESRXRX
Market Cap
$10.51B$1.78B
Sector
UtilitiesHealth
52-Week High
$17.28$6.79
52-Week Low
$12.51$2.84
Enterprise Value
$40.77B$1.30B
Dividend Yield
4.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AES Corp

AES trades at $14.73, up 0.2% on the day, with a bullish technical signal supported by moving averages. The company reported strong profitability with a net income margin of 14.34% and ROE of 45.05% for 2025, though Q2 2026 EPS missed expectations. A pending $33.4 billion acquisition by a consortium led by Global Infrastructure Partners and EQT, approved by stockholders, dominates recent developments, alongside a consistent dividend payout.

The acquisition offers a near-term catalyst with a capped upside at the buyout price of $15 per share, presenting a low-risk arbitrage opportunity. Risks include deal completion uncertainty amid shareholder complaints and regulatory scrutiny. Analyst consensus is mixed with 43% buy ratings, reflecting cautious optimism tied to the acquisition's successful closure and the company's strategic shift toward renewable energy investments.

Recursion Pharmaceuticals Inc

RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.

Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AES Corp

AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.

Read more on AES

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX